Joakim Bergman1, Joachim Burman2, Tommy Bergenheim1, Anders Svenningsson3,4. 1. Department of Clinical Science, Umeå University, Umeå, Sweden. 2. Department of Neurosciences, Uppsala University, Uppsala, Sweden. 3. Department of Clinical Science, Umeå University, Umeå, Sweden. anders.svenningsson@ki.se. 4. Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Danderyd Hospital, 182 88, Stockholm, Sweden. anders.svenningsson@ki.se.
Abstract
OBJECTIVES: To evaluate the effect of intrathecally (IT) delivered rituximab as a therapeutic intervention for progressive multiple sclerosis (PMS) during a 3-year follow-up period. METHODS: Participants of a 1-year open-label phase 1b study of IT delivered rituximab to patients with PMS were offered extended treatment with follow-up for an additional 2 years. During the extension phase, treatment with 25 mg rituximab was administered every 6 months via a subcutaneous Ommaya reservoir connected to the right frontal horn with a ventricular catheter. RESULTS: Mild to moderate vertigo and nausea occurred in 4 out of 14 participants as temporary adverse events associated with IT rituximab infusion. During the entire 3-year period, two cases of low-virulent bacterial meningitis occurred, which were successfully treated. Walking speed deteriorated significantly during the study. CONCLUSIONS: IT administration of rituximab via a ventricular catheter was well tolerated. Considering the meningitis cases, the risk of infection was not negligible. The continued loss of walking speed indicates that IT rituximab was not able to stop disease progression. CLASSIFICATION OF EVIDENCE: This study provides class IV evidence that intraventricularly administered rituximab in progressive MS is associated with a risk for bacterial meningitis and does not halt disease progression. EU CLINICAL TRIAL REGISTER: EudraCT; 2008-002626-11 and 2012-000721-53.
OBJECTIVES: To evaluate the effect of intrathecally (IT) delivered rituximab as a therapeutic intervention for progressive multiple sclerosis (PMS) during a 3-year follow-up period. METHODS: Participants of a 1-year open-label phase 1b study of IT delivered rituximab to patients with PMS were offered extended treatment with follow-up for an additional 2 years. During the extension phase, treatment with 25 mg rituximab was administered every 6 months via a subcutaneous Ommaya reservoir connected to the right frontal horn with a ventricular catheter. RESULTS: Mild to moderate vertigo and nausea occurred in 4 out of 14 participants as temporary adverse events associated with IT rituximab infusion. During the entire 3-year period, two cases of low-virulent bacterial meningitis occurred, which were successfully treated. Walking speed deteriorated significantly during the study. CONCLUSIONS: IT administration of rituximab via a ventricular catheter was well tolerated. Considering the meningitis cases, the risk of infection was not negligible. The continued loss of walking speed indicates that IT rituximab was not able to stop disease progression. CLASSIFICATION OF EVIDENCE: This study provides class IV evidence that intraventricularly administered rituximab in progressive MS is associated with a risk for bacterial meningitis and does not halt disease progression. EU CLINICAL TRIAL REGISTER: EudraCT; 2008-002626-11 and 2012-000721-53.
Authors: J A Cohen; G R Cutter; J S Fischer; A D Goodman; F R Heidenreich; M F Kooijmans; A W Sandrock; R A Rudick; J H Simon; N A Simonian; E C Tsao; J N Whitaker Journal: Neurology Date: 2002-09-10 Impact factor: 9.910
Authors: Joakim Bergman; Joachim Burman; Jonathan D Gilthorpe; Henrik Zetterberg; Elena Jiltsova; Tommy Bergenheim; Anders Svenningsson Journal: Neurology Date: 2018-10-10 Impact factor: 9.910
Authors: Stephen L Hauser; Amit Bar-Or; Giancarlo Comi; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Xavier Montalban; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Jerry S Wolinsky; Douglas L Arnold; Gaelle Klingelschmitt; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Peter Chin; Nicole Mairon; Hideki Garren; Ludwig Kappos Journal: N Engl J Med Date: 2016-12-21 Impact factor: 91.245
Authors: Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky Journal: N Engl J Med Date: 2016-12-21 Impact factor: 91.245
Authors: James L Rubenstein; Jane Fridlyand; Lauren Abrey; Arthur Shen; Jon Karch; Endi Wang; Samar Issa; Lloyd Damon; Michael Prados; Michael McDermott; Joan O'Brien; Chris Haqq; Marc Shuman Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: Jeffrey A Cohen; Arun V Krishnan; Andrew D Goodman; James Potts; Ping Wang; Eva Havrdova; Chris Polman; Richard A Rudick Journal: JAMA Neurol Date: 2014-11 Impact factor: 18.302
Authors: Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith Journal: Ann Neurol Date: 2009-10 Impact factor: 10.422